首页> 外国专利> Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy

机译:周细胞凋亡抑制剂在治疗和/或预防糖尿病性视网膜病中的用途

摘要

The use of a retinal pericyte apoptosis inhibitor (I) is claimed in the production of a medicament for treating or preventing diabetic retinopathy. An independent claim is included for pharmaceutical compositions containing (I). ACTIVITY : Antidiabetic; Ophthalmological. MECHANISM OF ACTION : Retinal pericyte apoptosis inhibitor; Antioxidant; Phosphatidylcholine phospholipase C inhibitor; Acid sphingomyelinase inhibitor; Caspase inhibitor. In tests in cultured bovine pericytes, tricyclo (5,21,0(2,6)) decyl-9(8)-xanthate (D609) (Ia) at a concentration of 9.4 MicroM inhibited advanced glycosylation end product (AGE)-methylglyoxal induced ceramide production by 95%, diacyl glycerol (DAG) production by 80% and apoptosis by 40%.
机译:在生产用于治疗或预防糖尿病性视网膜病的药物中要求保护视网膜周细胞凋亡抑制剂(I)的用途。对于包含(I)的药物组合物包括独立权利要求。活动:抗糖尿病;眼科的作用机理:视网膜周细胞凋亡抑制剂。抗氧化剂磷脂酰胆碱磷脂酶C抑制剂;酸性鞘磷脂酶抑制剂;半胱天冬酶抑制剂。在培养的牛周细胞中的测试中,浓度为9.4 MicroM的三环(5,21,0(2,6))癸基9(8)-黄药(D609)(Ia)抑制了晚期糖基化终产物(AGE)-甲基乙二醛诱导神经酰胺的产生为95%,二酰基甘油(DAG)的产生为80%,凋亡为40%。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号